#
Title
1

Treatment Options for Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

2

Symptoms of Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

3

Diagnostic Lab Tests in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

4

Genetic Testing in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

5

Understanding NCCN Guidelines in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

6

Risk Factors for Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

7

Epidemiology of Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

8

Pancreatic Cancer Anatomy- Gastrointestinal Cancers OncInsights 2025-26

9

Staging and Prognosis in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

10

Diagnostic Imaging in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26

11

Advanced Basal Cell Carcinoma

12

Management of High-Risk Basal Cell Carcinoma

13

Management of Low-Risk Basal Cell Carcinoma

14

Skin Cancer Treatment for Non-Surgical Candidates

15

Basal Cell Carcinoma- Risk Factors and Diagnosis

16

Systemic Therapy for Skin Cancer

17

Should I Have Mohs Surgery?

18

Melanoma: Warning Signs and Risk Management

19

Follow Up and Prevention for Basal Cell Carcinoma

20

Utilizing Mohs Surgery for Skin Cancer Treatment

21

Basal and Squamous Cell Carcinoma: An Overview

22

Skin Cancer Facts and Figures

23

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer

24

Trials in ALK+ NSCLC: The Crown Study- 2024 Leading Developments in Lung Cancer

25

Limited Stage Small Cell Lung Cancer: The Adriatic Study- 2024 Leading Developments in Lung Cancer

26

Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung Cancer

27

Tarlatamab for Extensive Stage Small Cell Lung Cancer- 2024 Leading Developments in Lung Cancer

28

Staging Skin Cancer

29

Advances in Thyroid Cancer Treatment

30

Incurable HPV Negative Head and Neck Cancer

31

Recurrent/Metastatic HPV Positive Head and Neck Cancer

32

Curable HPV Negative Head and Neck Cancer

33

Curable HPV Positive Head and Neck Cancer

34

What is a Bone Marrow Transplant?

35

Q&A: Do People in Rural Communities Have Equal Access to Treatment Options?

36

Q&A: Is my Clinical Trial Affecting my Body's Reaction to the Covid-19 Vaccine?

37

Bispecific Antibodies in Myeloma: Approvals and Clinical Trials

38

Curative Strategies for Patients with Smoldering Multiple Myeloma

39

Management of Bispecific Antibodies Side Effects

40

Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data

41

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

42

Barriers to Biomarker Testing: Cost and Insurance

43

Barriers to Biomarker Testing: Ordering Tests

44

The Adaura Trial: The Effect on EGFR+ Treatment

45

Biomarker Driven Therapy for NSCLC

46

Current Recommendations and Best Practices for Biomarker Testing

47

The Importance of Biomarker Testing: What is Liquid Biopsy?

48

Biomarkers in NSCLC

49

Key Points from the Adaura Trial: Osimertinib

50

Biomarkers in NSCLC

51

The Importance of Biomarker Testing: What is Liquid Biopsy?

52

Barriers to Biomarker Testing: Cost and Insurance

53

Neoadjuvant Treatment for Patients with NSCLC

54

The Alina Trial for ALK+ NSCLC

55

Local Therapy for Limited Metastatic NSCLC

56

Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation

57

Treatment Options for Patients with Locally Advanced Unresectable NSCLC

58

Local Therapy for NSCLC Patients After Frontline Therapy

59

The Role of the Patient as Advocate

60

Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation

61

Local Therapy for Patients with Oligoprogressive NSCLC

62

The Future of Local Therapy in Lung Cancer

63

Adding to Targeted Therapy: Current Statistics and Biology

64

The Importance of Prostate Cancer Screening

65

सामान्य परामर्श मुद्दे (Common Consultation Issues)

66

पुरुषत्वीकरण चिकित्सा और द्वितीय एरिथ्रोसाइटोसिस (Masculinizing Therapy and Secondary Erythrocytosis)

67

सिकल सेल रोग और जेंडर अफर्मिंग हार्मोन थेरेपी (Sickle Cell Disease and Gender Affirming Hormone Therapy)

68

फेमिनाइजिंग थेरेपी और थ्रोम्बोसिस (Feminizing Therapy and Thrombosis)

69

भारत में ट्रांसजेंडर मुद्दे (Transgender Issues in India)

70

Neoadjuvant Therapy in Melanoma: Does It Give a Better Immune Response?

71

Neoadjuvant Therapy for Melanoma

72

Adjuvant Therapy for Melanoma

73

Adjuvant Therapy in Stage 3 and 4 Melanoma

74

Patient Selection for First Line Therapy in Stage 4 Melanoma

75

Neoadjuvant Therapy in Melanoma: The PRADO Trial

76

Major Advances in Uveal Melanoma

77

Clinical Trials in Melanoma

78

Incidence Trends in Melanoma

79

Side Effects of Immunotherapy in Melanoma

80

Treatment for Metastatic Melanoma

81

BRAF Mutated Melanoma

82

Melanoma and Current Treatment Options

83

Emerging Types of CAR T-Cell Therapy

84

CAR T-Cell Therapy Side Effects

85

CAR T-Cell Therapy for Patients with Relapsed Diffuse Large B-Cell Lymphoma

86

Treatment Options for Relapsed Diffuse Large B-Cell Lymphoma

87

Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: Bispecific Antibodies

88

Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: CAR-T Cells

89

Covid-19 and Lung Cancer Screening

90

Who Should Receive Lung Cancer Screening?

91

What is Involved in Lung Cancer Screening?

92

Timelines in Cancer Care

93

Efficiency and Effectiveness of Cancer Care

94

Is My Lung Cancer Mutation Genetic?

95

The Prevalence of Breast Cancer and Tools for Early Detection

96

Types of Imaging Tests for Breast Cancer

97

Anomalies on Breast Cancer Imaging: Next Steps

98

The Importance of Patient Centered Care

99

Symptoms of Breast Cancer

100

Key Players for Lung Cancer Program Success

101

Treatment After Diagnosis of Breast Cancer

102

Goals of Lung Cancer Advocacy

103

The Importance of Breast Cancer Screening

104

Prevalence of EGFR-Mutant NSCLC in Asian and Caucasian Communities

105

Advancements of Targeted Therapy for EGFR Mutations in NSCLC

106

Choosing First Line Therapy in EGFR Mutations

107

Osimertinib and the FLAURA Trial

108

Preferential Timing for Molecular Testing in NSCLC

109

Immunotherapy Before Surgery in NSCLC

110

Immunotherapy for Patients with Driver Mutation

111

Immunotherapy for Oligometastatic Disease

112

Gene Mutations in NSCLC

113

Testing Methodology for NSCLC: Immunohistochemistry

114

Testing Methodology for NSCLC: FISH

115

Testing Methodology for NSCLC: PCR Testing

116

Testing Methodology for NSCLC: Next Generation Sequencing (NGS)

117

Circulating Tumor DNA in NSCLC

118

Mesothelioma Updates, Episode 6: Peritoneal Disease

119

Mesothelioma Updates, Episode 5: Future Approaches

120

Mesothelioma Updates, Episode 4: Chemo and Immunotherapy

121

Mesothelioma Updates, Episode 3: Surgical Options

122

Mesothelioma Updates, Episode 2: Diagnosis and Staging

123

Mesothelioma Updates, Episode 1: Epidemiology

124

Targeted Therapy Forum, Episode 10: Cost and Treatment Options

125

Targeted Therapies Forum, Episode 9: Telemedicine and Cancer

126

Targeted Therapies Forum, Episode 8: Detecting TKI Resistance with Liquid Biopsy

127

Targeted Therapies Forum, Episode 7: Pleural Fluid or Blood Biopsy?

128

Targeted Therapies Forum, Episode 6: Coverage, Cost, and Standard of Care for Biopsy

129

Targeted Therapies Forum, Episode 5: Circulating Tumor DNA

130

Targeted Therapies Forum, Episode 4: Diagnosis and Testing Relevance

131

Targeted Therapies Forum, Episode 2: The Complimentary Use of Liquid and Tissue Biopsies

132

Targeted Therapies, Episode 3: Anxiety and Symptom Burden

133

Targeted Therapies Forum 2021, Episode 1: Liquid and Tissue Biopsies in Acquired Resistance

134

Melanoma Updates - Molecular Profiling and Driver Mutations in Melanoma Treatment

135

Melanoma Updates - The Importance of Screening for Skin Cancers

136

Melanoma Updates -- Leptomeningeal Disease/ Brain Mets in Melanoma

137

Melanoma Updates The Role of Neoadjuvant Treatment in Melanoma Care

138

Melanoma Updates Treatment Options for Metastatic Melanoma

139

Melanoma Updates Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma

140

Brain Metastases in Breast Cancer Treatment Options and Efficacy

141

Brain Metastases in Breast Cancer Risks of Developing Brain Metastasis in Breast Cancer

142

Telemedicine vs. In-Person Treatment: What Have we Learned?

143

Is There a Place for Telemedicine in Oncology?

144

Opening Up and Masking: Is it Safe?

145

The Oncologist's Role: Educating Patients During a Pandemic

146

The Variable Acceptance of the Covid Vaccine

147

Brain Metastases in Breast Cancer Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases

148

Brain Metastases in Breast Cancer, Prognosis and Impact on Survival

149

Melanoma Updates - Adjuvant Treatment Options for Melanoma

150

Metastatic Triple Negative Breast Cancer Immunotherapy Treatment Options and Potential Side Effects

151

Recent Data and Developments in Palliative Head and Neck Cancer Treatments

152

Palliative Care and Studies for Incurable Head and Neck Cancers

153

HPV and Head and Neck Cancers

154

Curative Modalities and Immunotherapy for Head and Neck Cancers

155

Metastatic Triple Negative Breast Cancer Antibody-Drug Conjugate Treatment Options

156

Metastatic Triple Negative Breast Cancer Targeted Therapy Treatment Options and Potential Side Effects

157

Surgical Management in Breast Cancer Body Image and Reconstruction Surgery

158

Surgical Management in Breast Cancer What to Expect During Surgery

159

Surgical Management in Breast Cancer Long Term Outcomes - Breast Conserving Therapy vs. Mastectomy

160

Surgical Management in Breast Cancer What to Expect After Surgery

161

Surgical Management in Breast Cancer The Role of Different Types of Surgery and the Management of Patients with Breast Cancer

162

Surgical Management in Breast Cancer Prophylactic Mastectomy on the Opposite Breast

163

Brain Metastases in Breast Cancer Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer

164

Surgical Management in Breast Cancer Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND)

165

GraceCAST 2021 Spanish COVID Panel-Vacunas contra el COVID en pacientes con cancer

166

GraceCAST 2021 Spanish COVID Panel- Usos de la Telemedicina para pacientes con cancer

167

GraceCAST Spanish COVID Panel-Impacto de la Covid-19 en la atención de pacientes con cáncer

168

GraceCAST Podcast-2021 English Q1 COVID Panel- COVID-19 Variants and the Challenge for Cancer Care

169

GraceCAST Podcast-2021 English Q1 COVID Panel- What Patients Should Expect Post COVID-19 Vaccination

170

GraceCAST Podcast-2021 English Q1 COVID Panel- The Continued Use of Telemedicine in Cancer Treatment

171

GraceCAST Podcast-2021 English Q1 COVID Panel- Is the COVID-19 Vaccine Safe For Cancer Patients

172

GraceCAST 2021 COVID Panel - Changes and Challenges of Consistent Cancer Care During the Pandemic

173

GraceCAST 2021 COVID Panel - COVID 19 Pandemic and the Impact on Cancer Care

174

GRACECast - Are there alternatives to radiation for patients with brain metastases

175

GRACECast - What is the optimal treatment for patients with advanced NSCLC and a BRAF-V600E mutation

176

GRACECast - What is tumor mutational burden TMB and could it be helpful in lung cancer management today

177

GRACECast - Treatment Options for Metastatic NSCLC

178

GRACEcast - Are there treatment options for patients with HER-2 NSCLC

179

PODCAST-GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- KRAS

180

GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- EGFR Exon 20

181

GRACEcast- ASCO LUNG 2020- Enhertu and the Potential for Treatment of HER2 Positive NSCLC

182

GRACEcast- ASCO LUNG 2020- The SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC

183

GRACEcast- ASCO LUNG 2020- New Potential Treatments for MET and RET Positive NSCLC Capmatinib-Tabrecta and BLU-667-Pralsetinib

184

GRACECast - LCVL Can EGFR inhibitor therapy treat and prevent brain metastases

185

GRACECast - LCVL- What are the options after a patient with an ALK-positive advanced NSCLC develops resistance on Alecensa-alectinib

186

GRACECast - LCVL - Can immunotherapy help frail patients with advanced NSCLC

187

GRACECast - LCVL What is the role of immunotherapy for unresectable Stage 3 NSCLC today

188

GRACECast - LCVL - H. Jack West MD - Can ALK inhibitors treat and prevent brain metastases

189

GRACECast - LCVL - Can blood-based mutation-testing help shape treatment decisions for advanced NSCLC

190

GRACECast - LCVL - Consolidation immunotherapy after chemo-radiation for stage 3 unresectable NSCLC

191

GRACECast - LCVL -Can local therapies improve outcomes for stage IV NSCLC?

192

GRACECast - LCVL - Could pre-operative immunotherapy improve outcomes in early stage NSCLC

193

GRACECast - LCVL - Leading treatment options for patients with low or negative tumor PD-L1 expression and advanced nonsquamous NSCLC today

194

GRACECast - LCVL - Can patients with an EGFR mutation-positive advanced NSCLC benefit from immunotherapy

195

GRACEcast - LCVL - What are the leading first line treatment options for advanced NSCLC harboring an ALK rearrangement today

196

GRACEcast - LCVL - Can immunotherapy help patients with small cell lung cancer

197

GRACEcast - LCVL - Leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today

198

GRACEcast - LCVL - What is the best first line treatment for patients with advanced EGFR mutation-positive NSCLC today

199

GRACEcast - LCVL - Which patients with advanced NSCLC are good candidates for first line immunotherapy alone today

200

GRACEcast - LCVL What is the current standard of care for patients with extensive stage small cell lung cancer

201

GRACEcast - Treatment options for patients with NSCLC and high tumor PD-L1 expression

202

GRACEcast - Treatment options for patients with advanced NSCLC and a HER2- ERBB2 mutation

203

GRACECast - Does immunotherapy have activity in malignant pleural mesothelioma

204

GRACEcast - Leading Treatment Options for Patients with Negative Tumor PD-L1 NSCLC with Dr. Stephen Liu

205

GRACEcast - Immunotherapy for Small Cell Lung Cancer with Dr. Stephen Liu

206

GRACEcast - Emerging Molecular Targets in NSCLC- RET Fusions with Dr. Josh Bauml

207

GRACEcast - Emerging Molecular Targets in NSCLC- MET with Dr. Josh Bauml

208

GRACEcast 2020 - Updates in Small Cell Lung Cancer with Dr. Jared Weiss

209

GRACEcast 2020 - New TKIs for Stage IV Non Small Cell Lung Cancer Mutations with Dr. Jared Weiss

210

GRACEcast 2020- Treatment Option Explored in the ADAURA Trial with Dr. Jared Weiss

211

Case Based Panel Discussion - EGFR Mutation Patient Progression and Next Steps

212

Case Based Panel Discussion - EGFR Mutation and High PDL1 - What is the Role of Immunotherapy in Treatment Decisions

213

Case Based Panel Discussion - EGFR Mutation with MET Amplification Treatment Decisions and the Importance of the Level of MET Amplification

214

Webside Discussions Update - Pt 3 - Challenges and the Future for In Person Patient Care

215

Webside Discussions Update Pt 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic

216

Webside Discussion Update Part 1- How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care

217

Case Based Panel Discussion - What is the Recommended Treatment for Common EGFR Mutations

218

Case Based Panel Discussion - EGFR Mutation Treated with Tagrisso Progression While on Treatment, and What is the Role of Repeat Biopsy

219

Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 3

220

Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 2

221

Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 1

222

Case Based Panel Discussion - EGFR Mutation Oligoprogression in Brain and or Body vs Worsening Progression What are the Treatment Options?

223

Case Based Panel Discussion 3.1 EGFR Mutation - Chemotherapy and an EGFR Inhibitor Concurrently or Sequentially in Treatment Decisions?

224

Case Based Panel Discussion 2.2 Patient with Asymptomatic Brain Metastases -Focal Radiation Before Alk Inhibitor or Begin with ALK Inhibitor

225

Case Based Panel Discussion 2.1 Patient with Good Performance Status, Lung Adenocarcinoma, Metastatic Disease Adrenal Lesion

226

Case Based Panel Discussion 2.4 Initial Brain Mets Progression in Body After Success on ALK Inhibitor

227

Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination Therapies

228

Case Based Panel Discussion 2.3 Developing Resistance to Alk Inhibitors, Areas of Progression After Years of Success Treatment Approach

229

Case Based Panel Discussion 2.7 Clinical Significance of HER2 Mutation How Does a Positive HER2 Mutation Effect Treatment Decisions in NSCLC

230

Case Based Panel Discussion 2.6 ALK Positive and High PDL1 First Line Treatment for Potentially Competing Targets

231

Case Based Panel Discussion 2019 3. EGFR Uncommon Exon 20 Mutation - Suggested Treatments Targeted Therapy and Clinica Trial

232

Corona Virus and Covid 19 - Key Questions Part Four - Is the Standard Care Changing for Cancer Patients Because of the Pandemic?

233

Corona Virus and Covid 19 - Key Questions Part Three - What Preventive Measures are Trustworthy?

234

Corona Virus and Covid 19 - Key Questions Part Two - Do Cancer Patients Have a Higher Risk?

235

Corona Virus and Covid 19 - Key Questions Part One - Should Cancer Patients Get Tested?

236

Case Based Panel Discussion 2019 3.2 EGFR Mutation and the FLAURA Trial, Is There a Difference in Data Based on Demographics

237

Unresectable NSCLC - Does Checkmate 227's Suggestion of an Immunotherapy Combination of Yervoy and Opdivio Offer Another Treatment Option?

238

Unresectable NSCLC - Tumor Mutational Burden (TMB), the Value in Testing

239

Unresctable NSCLC - Concurrent Chemo & Radiation, Followed By Immunotherapy, Potential Pneumonitis Following Durvalumab (Imfinzi)

240

Unresectable NSCLC - For Varying Patient Scenarios, Fragile Patient, Attrition after 8-9 Months, What is the Best Schedule for Durvalumab

241

Unresectable NSCLC - Treatment Standard Concurrent Chemo & Rad Followed by Immunotherapy, Approach for Patients with PDL1 Score of 0

242

Unresectable NSCLC - Does Timing of Treatment Make a Difference in Response

243

Unresectable NSCLC In a Frail Patient with Competing Risks Is the Standard Treatment the Best Approach

244

Unresectable NSCLC - Should Molecular Tests Be Considered and Would Outcome Effect Treatment Decisions